Vol 9, No 5 (October 2020): Chinese Clinical Oncology

Multidisciplinary Sarcoma Tumor Board2

Multidisciplinary sarcoma tumor board: adolescent and young adult soft tissue sarcoma—myxoid liposarcoma and alveolar soft part sarcoma
Priya Jayachandran, Dakshesh Patel, James Hu, Omar Ragab, Jennifer Ho, Kristi Lara, Alisa Ching, Connor Wayman, William W. Tseng

Original Article

Safety and efficacy of aprepitant as mono and combination therapy for the prevention of emetogenic chemotherapy-induced nausea and vomiting: post-marketing surveillance in China
Yunpeng Yang, Nong Yang, Lin Wu, Quchang Ouyang, Jian Fang, Jinfeng Li, Wangjun Liao, Kaican Cai, Jianjin Huang, Jin Li, Yiping Zhang, Xiaojia Wang, Helong Zhang, Nong Xu, Qiong Zhao, Xingsheng Hu, Wei Li, Wei Zhong, Diansheng Zhong, Gang Cheng, Sheng Ye, Meizuo Zhong, Dong Wang, Hui Liu, Jihua Zheng, Xiaojian Liu, Hong Xu, Li Zhang

Review Article

Imaging and diagnostic approach of the adnexal mass: what the oncologist should know
Sara E. Vázquez-Manjarrez, O. Cristina Rico-Rodriguez, Nancy Guzman-Martinez, Verónica Espinoza-Cruz, Denny Lara-Nuñez
How far should we go in optimal cytoreductive surgery for ovarian cancer?
Luis A. Hernandez-Lopez, Angel Elizalde-Mendez

Case Report

Breast carcinoma metastasis in a resected meningioma with early diagnosis of oligometastatic disease: a case report
Christian Fernandez, Louis Cappelli, Sara Chapin, Lawrence Kenyon, Christopher J. Farrell, Wenyin Shi

Disclosure:

1. The series “Targeting the DNA Damaging Pathway: PARPi and Beyond” was commissioned by the Editorial office, Chinese Clinical Oncology without any sponsorship or funding. Shaheenah Dawood served as the unpaid Guest Editor for the series.

2. The series “Multidisciplinary Sarcoma Tumor Board” was commissioned by the Editorial office, Chinese Clinical Oncology without any sponsorship or funding. William Tseng is serving as the unpaid Guest Editor for the series.